PhRMA Executive Vice President Chip Davis
Chester “Chip” Davis, Jr. is the Executive Vice President for Advocacy and Member Relations at PhRMA. He leads PhRMA’s federal, state and international government relations and advocacy efforts, and is also responsible for membership recruitment and retention.
Working at the intersection of public policy, healthcare and business, Mr. Davis is a leading national advocate for a strong, innovative biopharmaceutical research sector that seeks to serve patient needs and contribute to a strong US economy. He is a recognized expert on science, healthcare, economic and regulatory policies and how they affect a growing, innovative biopharmaceutical research industry.
Mr. Davis is a 20 year veteran of the biopharmaceutical sector. Prior to joining PhRMA, he was Vice President of Corporate External Relations for AstraZeneca, where he oversaw the company’s government relations, strategic alliances, community relations and employee volunteer efforts. He also was a member AstraZeneca’s Corporate Affairs Leadership team, and Vice-Chairman of the company Political Action Committee. In 2007, Mr. Davis was one of the inaugural winners of the AstraZeneca CEO Award, given to global executives who best demonstrate AstraZeneca leadership capabilities in their accomplishments.
Mr. Davis earned an undergraduate degree in Accounting from the University of Delaware, and a Juris Doctor from the University of Baltimore School of Law. He currently serves on the Board of Directors for the Global Intellectual Property Center, the University of Delaware Alumni Association, the St. Mary’s High School Royal Blue Club, the Government Affairs Committee for Autism Speaks, and the Member Advisory Board for the National Journal.
- U.S. Rep Clyburn explains how clinical trials provide opportunity to address health disparities
- U.S. policymakers can't ignore storm clouds from India
- Protecting IP: Balancing current and future interests
Page last updated 02/04/14 ~ 9:59 am EST
Related news stories / opinion pieces
Page last updated 02/03/14 ~ 1:55 pm EST